Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izaf110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Duo Hou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Biomarkers, Peroxidase, Crohn Disease. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: New Zealand Society of Gastroenterology, Royal Australasian College of Physicians.
Abstract (Originalsprache)
Background
Inflammatory bowel disease (IBD) is a relapsing-remitting illness requiring proactive monitoring of gut inflammation. We aimed to determine the correlations of plasma myeloperoxidase (pMPO) and calprotectin (pCal), two neutrophil proteins, with existing measures of disease activity.
Methods
Adults with IBD undergoing ileocolonoscopy were recruited prospectively. Baseline assessments included blood tests (pMPO, pCal, and C-reactive protein ([CRP]), symptom questionnaires, and endoscopic indices (simple endoscopic score for CD [SES-CD] and UC endoscopic index of severity [UCEIS]). Active IBD was defined as SES-CD > 2 and UCEIS ≥ 2. Spearman’s rank correlations assessed the associations between blood markers and endoscopic activity. The area under the receiver operating characteristics curves (AUROC) and univariable logistic regression assessed the ability of blood markers (at optimal thresholds) to identify active disease.
Results
In total, 170 participants were included (female, n = 92; Crohn’s disease [CD], n = 99; median age 46 years, IQR 35-58). Plasma biomarkers more accurately identified active IBD in individuals with UC (AUROCpMPO = 0.76, P < .001; AUROCpCal = 0.66, P < .05; AUROCCRP = 0.73, P < .001) than in CD (AUROCpMPO = 0.62, P > .05; AUROCpCal = 0.65, P < .01; AUROCCRP = 0.66, P < .01). In all patients with IBD, the addition of pCal (AUROC = 0.73, P < .001) and pMPO (AUROC = 0.73, P < .001) to CRP added benefit compared to CRP (AUROC = 0.70, P < .001) alone. Plasma myeloperoxidase > 13.86 ng/mL (odds ratio [OR] = 10.13, 3.4-30.16) and pCal > 961.72 ng/mL (OR = 3.38, 1.21-9.4) were associated with an increased odds of having endoscopically active UC.
Conclusions
Plasma MPO shows promise as a potential blood-based biomarker of IBD activity, especially in UC. The combined use of pMPO and CRP adds diagnostic utility in discriminating between active versus quiescent IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
- Department of Gastroenterology, Christchurch Hospital, Christchurch, New Zealand.
- Mātai Hāora - Centre for Redox Biology and Medicine, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand.
ORCID-Profile: Akhilesh Swaminathan, Antony J Kettle, Richard B Gearry
Förderung
- New Zealand Society of Gastroenterology
- Royal Australasian College of Physicians
Zitieren
APA
Hou, D., Swaminathan, A., Borichevsky, G. M., Frampton, C. M., Kettle, A. J., & Gearry, R. B. (2025). Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf110
Vancouver
Hou D, Swaminathan A, Borichevsky GM, Frampton CM, Kettle AJ, Gearry RB. Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf110
BibTeX
@article{Hou2025,
author = {Hou, Duo and Swaminathan, Akhilesh and Borichevsky, Grace M and Frampton, Chris M and Kettle, Antony J and Gearry, Richard B},
title = {Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izaf110}
}
EUVIMED